Experienced in Venous Thromboembolism (VTE)

Dae S. Heo

Seoul, KR 
Experienced in Venous Thromboembolism (VTE)
Seoul, KR 
OverviewLocationsClinical Research

Overview

Dae Heo practices in Seoul, Republic of Korea. Mr. Heo is rated as an Experienced expert by MediFind in the treatment of Venous Thromboembolism (VTE). His top areas of expertise are EGFR Positive Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), and Laryngectomy.

His clinical research consists of co-authoring 235 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Venous Thromboembolism (VTE).

Gender
Male

Locations

Seoul, Republic of Korea
Other Locations
Republic of Korea
Songnam, Republic of Korea
Seongyeol Park, Koo, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Phase II Study of Rituximab Plus MG4101 in Patients With Relapsed or Refractory Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)
Phase II Study of Rituximab Plus MG4101 in Patients With Relapsed or Refractory Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Terminated
Publish Date: October 27, 2022
Intervention Type: Drug
Study Drugs: Rituximab, MG4101
Study Phase: Phase 2
A Phase II Study of Bendamustine Plus Rituximab (BR) in Patients With Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)
A Phase II Study of Bendamustine Plus Rituximab (BR) in Patients With Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)
Enrollment Status: Completed
Publish Date: September 24, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus
A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus
Enrollment Status: Completed
Publish Date: December 08, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trials

235 Total Publications

Broad-Spectrum Antibiotic Use at the End of Life in Patients With Advanced Cancer.
Broad-Spectrum Antibiotic Use at the End of Life in Patients With Advanced Cancer.
Journal: JAMA network open
Published: September 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Heo's expertise for a condition
ConditionClose
    View All 23 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile